About Us
Over the past 20 years we have seen dramatic advances in the science of developing new treatments, from immunotherapies to cell and gene therapies, and more recently mRNA vaccines. Technology has also become more sophisticated and is generating a volume of data that is growing exponentially.
However clinical research has not kept pace with these innovations, with clinical trials conducted much the same over the past 20 years. We believe that bringing this innovation to clinical research will mean more rapid and efficient trials, ensuring patients benefit sooner and from a larger array of treatments.
Through our 2 business units, Emmes, a Clinical Research Organization (CRO), and Veridix AI, a technology and analytics provider, we aim to modernize clinical research.
Veridix AI provides the technology backbone and generative AI platform that is purpose built for clinical research.
Emmes CRO will continue its 47-year history of scientific excellence with industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, and ophthalmology.
Where Human Intelligence Meets Artificial Intelligence
Bringing these companies together ensures both the development of a technology and AI infrastructure for clinical research, and adoption of those capabilities by retooling CRO processes to embed technology and AI into the full-service offering provided to customers.
The Emmes Group is dedicated to bringing clinical research forward into the 21st century.
Our Unified Platform
